^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DLL3 expression

    i
    Other names: DLL3, Delta Like Canonical Notch Ligand 3, Drosophila Delta Homolog 3, Delta-Like Protein 3, Delta3, Delta (Drosophila)-Like 3, Delta-Like 3 (Drosophila), Delta-Like 3, SCDO1
    Entrez ID:
    10683
    Related biomarkers:
    Expression
    3d
    A Phase 1, First-in-Human, Investigator-Initiated, Open-label Study to Assess the Safety, Feasibility, Cytokinetics, and Preliminary Antitumor Activity of GC511B in Adult Subjects with DLL3+ Relapsed/Refractory Small Cell Lung Cancer (ChiCTR2500111823)
    P1, N=100, Not yet recruiting, CancerCancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences Hospital
    New P1 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    7d
    Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression • DLL3 positive
    |
    cyclophosphamide • fludarabine IV
    20d
    Circulating Tumor Cells Predict Response to the DLL3-targeting Bispecific Antibody Tarlatamab. (PubMed, Cancer Discov)
    Acquired resistance to tarlatamab is associated in some cases with loss of DLL3 expression, but persistence of other targetable neuro-endocrine epitopes; in other patients, DLL3 is retained on CTCs, but accompanied by systemic markers of T cell dysfunction. Quantitation of DLL3-positive CTCs identifies patients likely to benefit from tarlatamab, and longitudinal monitoring may guide therapeutic decision-making at the time of acquired resistance.
    Journal • Circulating tumor cells
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression • DLL3 positive
    |
    Imdelltra (tarlatamab-dlle)
    24d
    Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Molecular Partners AG | Not yet recruiting --> Recruiting | Trial completion date: Sep 2030 --> Sep 2032
    Enrollment open • Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    29d
    Analysis of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, YAP1), DLL3, OTP, and TTF1 in 300 lung carcinoids and enteropancreatic neuroendocrine tumours. (PubMed, Histopathology)
    Unlike SCLC, lung carcinoids and EP-NETs completely lack the expression of POU2F3 and YAP1, which offers diagnostic applications. Our findings also nominate ASCL1 and NEUROD1 as site of origin markers for lung versus digestive NETs/carcinoids, respectively. Finally, the divergent expression of DLL3 in lung carcinoids and EP-NETs has therapeutic implications.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3) • YAP1 (Yes associated protein 1) • TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)
    |
    DLL3 expression
    2ms
    Tarlatamab for small-cell lung cancer. (PubMed, Expert Opin Biol Ther)
    Most data come from SCLC; in the other two diseases, tarlatamab is in early clinical development. Tarlatamab is an effective therapy mainly in relapsed/progressed SCLC, and its assessment in limited SCLC alone or combined with other therapies is supported by the existing data.
    Review • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    Imdelltra (tarlatamab-dlle)
    2ms
    Multi-center Assessment of DLL3 Expression by Immunohistochemistry in Medullary Thyroid Carcinoma. (PubMed, Endocr Pathol)
    Our findings indicate that DLL3 is frequently expressed in MTC and its high expression identifies tumors with aggressive pathological characteristics and poor clinical outcomes. These results support DLL3 as a potential prognostic biomarker and therapeutic target in MTC, highlighting the need for further validation and integration into clinical trials of DLL3-directed therapies.
    Retrospective data • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    2ms
    Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer. (PubMed, Mol Cancer)
    This multimodal profiling analysis provides further insights into the biologic complexity of SCLC and highlights potential therapeutic vulnerabilities of distinct disease subtypes.
    Journal • IO biomarker
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    2ms
    DLL3-targeted immunoPET and radioimmunotherapy ligands. (PubMed, Am J Nucl Med Mol Imaging)
    Several radioligands have been developed by targeting DLL3 for immunoPET or radioimmunotherapy use. These ligands hold great promise for mapping the heterogeneous DLL3 expression in neuroendocrine tumors and guiding the DLL3-directed therapeutic strategies.
    Journal • IO biomarker
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    2ms
    Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms. (PubMed, JCO Precis Oncol)
    DLL3 is expressed on a majority of GEP NECs and on a subset of high-grade PanNETs marked by poor outcomes. Functional imaging suggests DLL3 as a promising therapeutic target in both GEP NECs and high-grade PanNETs.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression • DLL3 positive
    3ms
    DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy. (PubMed, JTO Clin Res Rep)
    Tarlatamab appeared effective when added to osimertinib. Further analysis of the combination of bispecific DLL3 T-cell engager and EGFR tyrosine kinase inhibitor is warranted to confirm these findings.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RB1 mutation • DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tagrisso (osimertinib) • Imdelltra (tarlatamab-dlle)
    3ms
    A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)